Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.71 |
| ▸ | CTSL | P07711 | 4/20 | 0.71 |
| ▸ | CTSB | P07858 | 4/20 | 0.71 |
| ▸ | PPARA | Q07869 | 4/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | KYNU | Q16719 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400096 | 1.00 | CTSS (0.71) | CTSSCTSLCTSBPPARAPPARG | |
| SCHEMBL2400100 | 1.00 | CTSS (0.71) | CTSSCTSLCTSBPPARAPPARG | |
| SCHEMBL5134409 | 0.95 | CTSL (0.72) | CTSSCTSLCTSBPPARAPPARG | |
| SCHEMBL3044553 | 0.90 | CTSS (0.70) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL3292733 | 0.90 | CTSS (0.70) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL346954 | 0.89 | CTSS (0.58) | CTSSCTSLCTSBPPARAPPARG | |
| SCHEMBL346953 | 0.89 | CTSS (0.58) | CTSSCTSLCTSBPPARAPPARG | |
| SCHEMBL18775057 | 0.88 | CTSS (0.57) | CTSSCTSLCTSBPPARAPPARG | |
| SCHEMBL18775053 | 0.88 | CTSS (0.57) | CTSSCTSLCTSBPPARAPPARG | |
| SCHEMBL13863699 | 0.88 | CTSS (0.57) | CTSSCTSLCTSBPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718611-B2 | Cyclic nonapeptide amides | AICURIS GMBH & CO. KG (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718611-B2 | Cyclic nonapeptide amides | AICURIS GMBH & CO. KG (DE) | 2010-05-18 | — | — | US | disclosed |
| EP-1625153-B1 | ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES | AICURIS GMBH & CO KG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
| CN-101107265-A | Cyclic nonapeptide amides | AICURIS GMBH & CO KG (DE) | 2008-01-16 | — | — | CN | disclosed |
| EP-1809657-A1 | CYCLIC NONAPEPTIDE AMIDES | AiCuris GmbH & Co. KG (DE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048156-A1 | CYCLIC NONAPEPTIDE AMIDES | AICURIS GMBH & CO. KG (DE) | 2006-05-11 | — | — | WO | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | CTSS 459/4885CTSL 65/4885CTSB 110/4885 |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AAAS, PGLS, NRDC | CTSS 339/4885CTSL 360/4885CTSB 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.